Pharmaceuticals News and Research

RSS

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

Companion diagnostics is critical in helping to pave the way for personalized medicine, in which the treatment is adapted and precisely tailored to the patient.

From Siemens Healthineers 27 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Scientists finds link between protein phosphorylation and Parkinson's disease

Clues left at the scene of the crime don't always point to the guilty party, as EPFL researchers investigating Parkinson's disease have discovered. It is generally accepted that the disease is aggravated when a specific protein is transformed by an enzyme.

27 Aug 2013

Unique computer technology opens up discovery of smarter drugs to treat illnesses

A unique computer technology that opens up the discovery of smarter drugs to treat major illnesses including heart disease has been invented by University of Strathclyde scientists.

27 Aug 2013

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema.

26 Aug 2013

First Edition: August 26, 2013

Today's headlines include reports about the ongoing battles between those who support the implementation of the health law, and those who oppose it.

26 Aug 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

CeBiTec researchers successfully sequence genome of Chinese hamster

Genome researchers from Bielefeld University's Center for Biotechnology (CeBiTec) headed by Professor Dr. Alfred P-hler have succeeded in sequencing the genome of the Chinese hamster. The Chinese hamster supplies the cell cultures used by the pharmaceutical industry to produce biopharmaceutical products such as antibodies used in medicine.

26 Aug 2013

Local governments wrestle with employee hours and health coverage

Even though the requirement that employers -- including governments -- offer full-time employees health coverage does not kick in for 16 months, there are already changes, The Washington Post reports.

26 Aug 2013

First Edition: August 23, 2013

Today's headlines include reports on what's becoming of the potential for a deficit deal, as well as the political posturing related to the House GOP efforts to block health law funding even if it means shutting down the government.

23 Aug 2013

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space.

23 Aug 2013

Ultimate DIY book for laboratory chemists in search of next generation medicines

Pharmaceuticals of the future will be fashioned using the human body's own chemical substances, proteins and peptides. And now, University of Copenhagen chemists have published the ultimate DIY book for laboratory chemists in search of this next generation of medicines.

23 Aug 2013

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.

23 Aug 2013

Takeda Launches New Subsidiary In Peru

...

22 Aug 2013

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.

22 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

MicuRx Pharmaceuticals raises $25 million in Series B financing

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

22 Aug 2013

Use of psychotherapy on a clear decline in US

Psychotherapy has issues. Evidence shows that some psychosocial treatments work well for common mental health problems such as anxiety and depression and that consumers often prefer them to medication.

22 Aug 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

Pharmaceuticals News and Research

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

FDA grants Priority Review designation to sNDA for Nexavar tablets

Scientists finds link between protein phosphorylation and Parkinson's disease

Unique computer technology opens up discovery of smarter drugs to treat illnesses

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

First Edition: August 26, 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

CeBiTec researchers successfully sequence genome of Chinese hamster

Local governments wrestle with employee hours and health coverage

First Edition: August 23, 2013

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Ultimate DIY book for laboratory chemists in search of next generation medicines

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Takeda Launches New Subsidiary In Peru

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

MicuRx Pharmaceuticals raises $25 million in Series B financing

Use of psychotherapy on a clear decline in US

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence